|

Mid-afternoon market update: Dow falls 75 points; vTv Therapeutics (VTVT Stock) shares spike higher

Toward the end of trading Tuesday, the Dow traded down 0.22% to 33,669.76 while the NASDAQ rose 0.80% to 13,960.92. The S&P also rose, gaining 0.28% to 4,139.55.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 31,268,400 cases with around 562,530 deaths. India confirmed a total of at least 13,689,450 cases and 171,050 deaths, while Brazil reported over 13,517,800 COVID-19 cases with 354,610 deaths. In total, there were at least 136,727,030 cases of COVID-19 worldwide with more than 2,947,840 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors

Utilities shares rose 1.2% on Tuesday. Meanwhile, top gainers in the sector included Pure Cycle Corporation PCYO 4.24%, up 4%, and Companhia Energética de Minas Gerais CIG 2.81%, up 4%.

In trading on Tuesday, financial shares fell 0.7%.

Top Headline

Fastenal Company FAST 1.76% reported better-than-expected earnings for its first quarter.

Fastenal reported quarterly earnings of $0.37 per share, beating analysts’ estimates of $0.36 per share. The company’s quarterly sales came in at $1.42 billion, versus expectations of $1.42 billion.

Equities Trading UP

Mackinac Financial Corporation MFNC 59.15% shares shot up 56% to $20.56 after the company, and Nicolet Bankshares, jointly announced the execution of a definitive merger agreement, pursuant to which Nicolet will acquire Mackinac and its wholly-owned banking subsidiary, mBank.

Shares of NovoCure Limited NVCR 48.5% got a boost, shooting 49% to $196.55 after the company issued an update on Phase 3 pivotal LUNAR trial of tumor treating fields in non-small cell lung cancer.

vTv Therapeutics Inc. VTVT 35.76% shares were also up, gaining 40% to $3.5982 after the company said it received FDA breakthrough therapy designation for TTP399 for the treatment of Type 1 Diabetes.

Check out these big movers of the day

Equities Trading DOWN

Avenue Therapeutics, Inc. ATXI 25.6% shares tumbled 26% to $5.23 after the company announced FDA is still reviewing its NDA resubmission for IV tramadol and has not provided a decision.

Shares of Lucira Health, Inc. LHDX 18.33% were down 20% to $8.76 after B of A Securities downgraded the stock from Buy to Underperform and announced a price target of $9 per share.

Fortress Biotech, Inc. FBIO 8.49% was down, falling 14% to $4.7250. Fortress Biotech recently received a $7.5 million working capital line of credit.

Commodities

In commodity news, oil traded up 0.8% to $60.16, while gold traded up 0.7% to $1,745.30.

Silver traded up 2.1% Tuesday to $25.385 while copper rose 0.4% to $4.0335.

Euro zone

European shares closed mostly higher today. The eurozone’s STOXX 600 gained 0.12%, the Spanish Ibex Index fell 0.09% and the German DAX 30 gained 0.13%. Meanwhile, the French CAC 40 rose 0.36%, London’s FTSE 100 rose 0.02% and Italy’s FTSE MIB rose 0.59%.

The Eurozone’s ZEW Indicator of Economic Sentiment fell by 7.7 points to 66.3 in April, while German ZEW Indicator of Economic Sentiment declined 5.9 points to 70.7 in April. Italy’s industrial production rose 0.2% in February, while wholesale prices in Germany rose 4.4% year-over-year in March.

Imports to the UK climbed 12.9% to GBP 53.3 billion in February, while exports increased 5.4% to GBP 46.2 billion. Britain's GDP shrank by 1.6% during the three months to February, while industrial production rose 1% in February.

Economics

The NFIB Small Business Optimism Index rose to 98.2 in March from 95.8 in February.

Annual inflation rate in the US surged to 2.6% in March from 1.7% in February, also above analysts’ estimates of 2.5%.

The Johnson Redbook Retail Sales Index rose 13.2% year-over-year during the first full week of April.

Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 3:15 p.m. ET.

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to PremiumSign In

Author

Benzinga Team

Benzinga's news desk is a dynamic and innovative team that provides real-time, actionable articles that help readers navigate the market.

More from Benzinga Team
Share:

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

By subscribing you agree to our Terms and conditions.

Editor's Picks

EUR/USD bounces toward 1.1750 as US Dollar loses strength

EUR/USD returned to the 1.1750 price zone in the American session on Friday, despite falling Wall Street, which indicates risk aversion. Trading conditions remain thin following the New Year holiday and ahead of the weekend, with the focus shifting to US employment and European data scheduled for next week.

GBP/USD nears 1.3500, holds within familiar levels

After testing 1.3400 on the last day of 2025, GBP/USD managed to stage a rebound. Nevertheless, the pair finds it difficult to gather momentum and trades with modest intraday gains at around 1.3490 as market participants remain in holiday mood.

Gold trims intraday gains, approaches $4,300

Gold retreated sharply from the $4,400  area and trades flat for the day in the $4,320 price zone. Choppy trading conditions exacerbated the intraday decline, although XAU/USD bearish case is out of the picture, considering growing expectations for a dovish Fed and persistent geopolitical tensions.

Cardano gains early New Year momentum, bulls target falling wedge breakout

Cardano kicks off the New Year on a positive note and is extending gains, trading above $0.36 at the time of writing on Friday. Improving on-chain and derivatives data point to growing bullish interest, while the technical outlook keeps an upside breakout in focus.

Economic outlook 2026-2027 in advanced countries: Solidity test

After a year marked by global economic resilience and ending on a note of optimism, 2026 looks promising and could be a year of solid economic performance. In our baseline scenario, we expect most of the supportive factors at work in 2025 to continue to play a role in 2026.

Crypto market outlook for 2026

Year 2025 was volatile, as crypto often is.  Among positive catalysts were favourable regulatory changes in the U.S., rise of Digital Asset Treasuries (DAT), adoption of AI and tokenization of Real-World-Assets (RWA).